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Thyroid hormones play an essential role in brain development both during pre- and postnatal life. Unfortunately, clinical symptoms are often late, and nothing can be done at that 
point to save these children from permanent mental and physical 
handicap. Congenital hypothyroidism (CH) is one of the most 
common preventable causes of mental retardation. To identify the 
babies in an early stage, screening of babies in first few days of life 
is the only choice. Without prompt treatment, most of the affected 
children gradually develop growth failure, irreversible mental 
retardation, and a variety of neuropsychological deficits. Routine 
neonatal screening programs, which have been in operation over 
the past 4 decades in the most industrialized countries, have led 
to the successful early detection and treatment of infants with 
CH and have eliminated the severe neurodevelopmental deficits 
resulting from late diagnosis [1]. Studies on cognitive function in 
patients with CH treated soon after birth have shown that normal 
development can be achieved in most of the patients; although 
some may have subtle neurocognitive deficits [2].
Certain prenatal factors associated with neurodevelopmental 
deficits are etiology (dysgenesis), LBW, and severity of 
hypothyroidism [3]. Postnatal factors include the age of 
onset of treatment (>1 month), lower thyroxine dose at onset 
(< 8 μg/kg/day), late normalization of thyroid function (> 2 weeks 
after treatment), and a lower socioeconomic status [4,5]. Choosing 
initial dose of L-thyroxine at the higher end of the recommended 
range and achieving normal thyroid function at 1 or 2 weeks 
of therapy is important to achieve optimal neurodevelopmental 
outcome [6,7].
Estimates of the prevalence of CH vary according to the 
method of ascertainment: About 1 in 2000-3000 live births 
in countries with neonatal screening versus about 1 in 6700 
live births before the screening era [2]. Recent reports have 
indicated that the incidence of primary CH may be increasing 
in some countries, particularly for cases with a normally located 
(eutopic) thyroid gland and milder dysfunction. The reasons for 
this remain unclear [8] but may relate to changes in screening 
thresholds [9,10]. The first multicentric study screening above 
1 lakh neonates born throughout India was launched by the 
Indian Council of Medical Research National Task Force Team 
on Newborn Screening at AIIMS, New Delhi (2007-2012), and 
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the preliminary results reveal a much higher incidence of CH all 
over India at 1 in 1172, particularly in South Indian population 
(1 in 727) [11].
We planned this study to assess the neuromotor and 
neurocognitive development of babies at 12 months of age who 
are diagnosed to have CH and initiated on thyroxine treatment at 
birth at our center. Furthermore, to estimate the occurrence of CH 
among babies delivered in our hospital through thyroid screening.
METHODS
This descriptive study was conducted in SGMC hospital from 
January 2015 to December 2015 after obtaining approval from the 
Institutional Ethics Committee. All babies delivered (including 
babies born to euthyroid and hypothyroid mothers on L-thyroxine) 
during the study period were subjected to estimation of cord blood 
thyroid-stimulating hormone (TSH) (by electro chemiluminescent 
assay). Our study included all healthy term babies (≥37 weeks), 
preterm babies (<37 weeks), and sick babies admitted in neonatal 
intensive care unit (includes meconium aspiration syndrome and 
birth asphyxia). In preterm and sick babies requiring inotropes, 
venous TSH and FT4 levels were repeated at 72 h of age and at 
2 weeks of age irrespective of the normal range of cord blood 
TSH level (<20 uIU/ml) for delayed rise in TSH level. In healthy 
term babies with cord blood TSH level ≥20 uIU/ml, venous TSH 
and FT4 were repeated at 72 h of age (before hospital discharge). 
Cord blood was collected as the direct flow of blood from cord, 
labeled and sent to laboratory from delivery room for immediate 
analysis (by chemiluminescent assay) of TSH.
Venous TSH level ≥20 uIU/ml with low FT4 (below normal 
range for age) was considered as abnormal and initiated on 
treatment before discharge from the hospital. In all babies, 
L-thyroxine was initiated in the higher dose 15 μg/kg once daily 
in the early morning within 5 days of birth. Venous TSH and FT4 
were repeated at 2 weeks of L-thyroxine therapy for normalization 
of TSH and FT4 level. X-ray knee was taken in babies with 
elevated venous TSH (≥20 uIU/ml) to assess the severity of 
intrauterine hypothyroidism by the presence or absence of 
femoral or tibial epiphyses. Ultrasonography neck was performed 
to localize the position of thyroid gland. Radioisotope scan Tc 
99m (scintigraphy) thyroid scan without perchlorate discharge 
test was performed in babies with elevated TSH before initiation 
of thyroxine treatment. Babies on L-thyroxine treatment were 
followed up at regular intervals in the outpatient department for 
compliance of medication and for the assessment of neuromotor 
and neurocognitive development.
Denver developmental screening test (DDST-1) was 
performed at 4, 6, 9, and 12 months of age. DDST was done by 
our developmental therapist. DASII and developmental quotient 
(DQ) was planned at 1 year of age; however, these were not 
performed as all our congenital hypothyroid babies (9 babies) 
on L-thyroxine therapy had normal DDST in all domains of 
milestones at 9 months and 12 months of age. The babies on 
thyroxine treatment in our study will be followed for 3 years for 
assessment of development - DASII and DQ and the need for 
continuation of thyroxine treatment lifelong.
Statistical Analysis
The data were entered into the Microsoft Excel sheet, and the results 
were analyzed descriptively using SPSS statistics version 19. 
The proportion of babies with CH having neurodevelopmental 
impairment at 4, 6, 9, and 12 months and the frequency of 
occurrence of CH were calculated.
CONSENT
As screening for CH is being done in our hospital for the past 
10 years, a separate written parental consent was not obtained 
during the study period. Parents were informed about the 
screening protocol at the time of delivery.
RESULTS
In our study, a total number of babies underwent cord blood 
TSH estimation during the study period was 1387. Out of these 
1387 babies, 9 babies (0.6/100 live births) had elevated venous 
TSH and low FT4 at 72 h of the age and initiated on L-thyroxine 
treatment. None of our CH babies had birth asphyxia or critically 
ill to require inotropic support. We had only one preterm baby 
with elevated TSH level Table 1. Among 9 babies with CH, 
radionuclide isotope thyroid scan Tc99m (scintigraphy) was 
performed in 6 babies on postnatal day 4. Thyroid dysgenesis was 
detected in 4 babies, and 2 babies had organification defect. None 
of our babies had an absence of femoral or tibial epiphyses on 
X-ray knee.
In all babies, L-thyroxine was initiated in the higher dose 
(15 μg/kg/day) within 5 days of life. Venous TSH and FT4 
were repeated at 2 weeks of L-thyroxine therapy, and we could 
observe TSH and FT4 in the normal range at 2 weeks of initiation 
of treatment. Among those 9 babies with CH, 7 (77.8%) babies 
were born to mothers who had normal thyroid status in the 
antenatal period. This could be due to the presence of subclinical 
hypothyroidism among mothers undiagnosed in the antenatal 
period.
In our study, DDST-1 performed at 4, 6, 9, and 12 months 
showed a mild gross motor delay in the earlier age which was 
later normal. At 12 months of age, all our hypothyroid babies had 
normal development in all domains (Table 2).
DISCUSSION
Neonatal screening programs for CH have been highly successful 
and economically beneficial over the past four decades. Affected 
children are detected very soon after birth, mostly before clinical 
symptoms and signs become evident. Early detection and 
treatment prevent morbidity, particularly neurodevelopmental 
disabilities. Many studies have confirmed the early success of 
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congenital screening for normalizing the cognitive outcomes of 
children with severe primary CH [12,13].
In our study, 4 babies were detected to have thyroid dysgenesis 
on radionuclide isotope thyroid scan Tc99m, which was considered 
as one of the prenatal factors for neurodevelopmental deficits in 
CH [3]. Other prenatal factors are low birth weight (mean birth 
weight was 2820 gm in our study) and severity of hypothyroidism 
as assessed by the presence of intrauterine hypothyroidism 
(suggested by the absence of femoral and tibial epiphyses on 
X-ray knee) [3]. All our CH babies were initiated on L-thyroxine 
in the higher dose of range (15 μg/kg/day) within 5 days of age. 
Furthermore, we could achieve normal venous TSH and FT4 
levels at 2 weeks of initiation of the treatment in all our CH babies 
including babies with thyroid dysgenesis.
Gulshan et al. have shown that administering initial dose of 
10-15 μg/kg/day L-thyroxine and initiating it within the first 
2 weeks of age has a better intellectual outcome compared to 
treatment with dose of 5-10 μg/kg/day and with an age at onset 
of treatment later than 14 days [7]. A similar study by Joseph R 
has also shown that neurodevelopmental deficits exist in children 
whose median age of onset of treatment was >2 weeks [4]. 
Since the advent of newborn screening programs in 1980’s, the 
diagnosis and treatment of this condition are now provided in the 
first 2-3 weeks of birth in most of the regions. Although this is 
sufficient to prevent mental retardation, the children so identified 
as CH has mildly reduced IQs from expectation and experience 
subtle and specific neurocognitive deficits. This deficit is 
correlated with the severity of hypothyroidism at birth [14].
A long-term follow-up data on cognitive and motor function in 
children diagnosed to have CH and initiated on treatment within 
1 month have shown that it is the severity of CH before initiation 
of treatment is the important factor in determining the long-term 
cognitive and motor outcome rather than timing of treatment 
initiation [5,15].
Overt and subclinical hypothyroidism is common in women 
of reproductive age and during pregnancy. More recently, the 
potential adverse impact of maternal subclinical hypothyroidism 
and fetal hypothyroxinemia, on neurodevelopment outcomes in 
the offspring, has been recognized [16-18]. In our study, among 
those 9 babies with CH, 7 (77.8%) babies were born to mothers 
who had normal TSH in the antenatal period. This could be due 
to the presence of subclinical hypothyroidism among mothers 
undiagnosed in the antenatal period.
Those neonates with CH and on regular thyroxine treatment 
were followed prospectively for neurodevelopmental assessment. 
At 4 months, the proportion of neuromotor delay was 33% with 
decrease in the proportion of neuromotor delay on subsequent 
follow-up. At 6 months, 22% of babies detected to have 
neuromotor delay and at 9 and 12 months follow-up showed 
normal development in all domains (Table 2). As studies have 
shown [4-7] all our CH babies received initial dose of L-thyroxine 
at 15 μg/kg/day and initiated treatment within 5 days of age, and 
we could achieve the normal TSH at 2 weeks of initiation of 
treatment. None of our babies had absence of femoral or tibial 
epiphyses on x-ray knee suggesting intrauterine hypothyroidism.
The babies on thyroxine treatment in our study will be 
followed for 3 years for assessment of development - DASII and 
DQ will be performed and to decide on continuation of thyroxine 
treatment lifelong.
CONCLUSION
In our study, early detection of CH through universal neonatal 
screening for hypothyroidism and initiation of treatment in the 
1st week of age at 15 μg/kg/day with normalization of TSH 
at 2 weeks of initiation of treatment has resulted in normal 
neuromotor and neurocognitive development at 12 months of age.
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